journal
MENU ▼
Read by QxMD icon Read
search

Journal of Medical Economics

journal
https://www.readbyqxmd.com/read/28737468/economic-evaluations-of-haemophilus-influenzae-type-b-hib-vaccine-a-systematic-review
#1
Bunchai Chongmelaxme, Maythika Hammanee, Wariya Phooaphirak, Surachai Kotirum, Raymond Hutubessy, Nathorn Chaiyakunapruk
AIMS: World Health Organization (WHO) recommends the use of Haemophilus influenzae type b (Hib) conjugate vaccines but only China and Thailand have not used Hib vaccination in their national immunization programs. This systematic review aimed to update published economic evaluations of Hib vaccinations and to determine factors that potentially affected their cost-effectiveness. METHODS: Searching was performed from the inception until December 2015 using 13 databases: CAB direct; CEA registry; EconLit; EMBASE; E-library; NHSEED; PAHO; POPLINE; PubMed; Redalyc project; RePEc; SciELO and WHOLIS...
July 24, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28737052/the-importance-of-model-inputs-and-assumptions-in-conducting-health-technology-assessments-of-novel-drugs
#2
Tomas Philipson, Joanna P MacEwan
No abstract text is available yet for this article.
July 24, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28726530/incremental-net-monetary-benefit-of-ocrelizumab-relative-to-subcutaneous-interferon-%C3%AE-1a
#3
Melissa A Frasco, Tiffany Shih, Devin Incerti, Oliver Diaz Espinosa, Diana K Vania, Nina Thomas
AIM: Disease-modifying therapies (DMTs) impact the natural history of relapsing forms of multiple sclerosis (RRMS) by reducing annual relapse rates and slowing disability progression. The effect of DMTs on indirect costs has not been consistently explored in cost-effectiveness studies thus far. The value to patients of an emerging DMT, ocrelizumab, was quantified in comparison to subcutaneous interferon beta-1a (IFNβSC) for the prevalent RRMS population with mild to moderate disability in the United States based on two Phase 3 trials, OPERA I and OPERA II, of ocrelizumab versus IFNβSC in RRMS...
July 20, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28722494/cost-efficiency-analyses-for-the-us-of-biosimilar-filgrastim-sndz-reference-filgrastim-pegfilgrastim-and-pegfilgrastim-with-on-body-injector-in-the-prophylaxis-of-chemotherapy-induced-febrile-neutropenia
#4
Ali McBride, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham, Sanjeev Balu
AIMS: Guidelines recommend prophylaxis with granulocyte colony-stimulating factor for chemotherapy-induced (febrile) neutropenia (CIN/FN) based on regimen myelotoxicity and patient-related risk factors. Our aim was to conduct a cost-efficiency analysis for the US of the direct acquisition and administration costs of the recently approved biosimilar filgrastim-sndz (Zarxio® EP2006) with reference filgrastim (Neupogen(®)), pegfilgrastim (Neulasta(®)), and pegfilgrastim injection device (Neulasta Onpro(®); hereafter pegfilgrastim-injector) for CIN/FN prophylaxis...
July 19, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28720054/impact-of-novel-agents-on-patient-relevant-outcomes-in-patients-with-previously-untreated-cll-who-are-not-eligible-for-fludarabine-based-therapy
#5
Moushmi Singh, Stuart Mealing, Simona Baculea, Sarah Cote, Jo Whelan
BACKGROUND: Chronic lymphocytic leukemia (CLL) is an orphan disease that primarily affects the elderly. The majority of symptomatic patients eligible for frontline treatment are unfit for fludarabine based chemoimmunotherapy. Historical treatment includes chlorambucil (Chl), bendamustine/rituximab (BR), and chlorambucil/rituximab/ChlR combination. Clinical guidelines now recommend the use of novel agents, such as ibrutinib (Ibr), in both frontline and relapse settings and other novel agents, such as idelalisib (with rituximab), in relapse settings...
July 19, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28651479/evaluating-the-short-term-cost-effectiveness-of-liraglutide-versus-lixisenatide-in-patients-with-type-2-diabetes-in-the-united-states
#6
B Hunt, C C McConnachie, C Gamble, T Dang-Tan
AIMS: Bringing patients with type 2 diabetes to recommended glycated hemoglobin (HbA1c) treatment targets can reduce the risk of developing diabetes-related complications. The aim of the present analysis was to evaluate the short-term cost-effectiveness of once-daily liraglutide 1.8 mg vs once-daily lixisenatide 20 μg as an add-on to metformin for treatment of type 2 diabetes in the US by assessing the cost per patient achieving HbA1c-focused and composite treatment targets. MATERIALS AND METHODS: Percentages of patients achieving recommended targets were obtained from the LIRA-LIXI trial, which compared the efficacy and safety of once-daily liraglutide 1...
July 11, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28649943/cost-effectiveness-of-insulin-detemir-versus-insulin-glargine-for-thai-type-2-diabetes-from-a-payer-s-perspective
#7
Unchalee Permsuwan, Kednapa Thavorn, Piyameth Dilokthornsakul, Surasak Saokaew, Nathorn Chaiyakunapruk
AIMS: An economic evidence is a vital tool that can inform the decision to use costly insulin analogs. This study aimed to evaluate long-term cost-effectiveness of insulin detemir (IDet) compared with insulin glargine (IGlar) in type 2 diabetes (T2DM) from the Thai payer's perspective. METHODS: Long-term costs and outcomes were projected using a validated IMS CORE Diabetes Model, version 8.5. Cohort characteristics, baseline risk factors, and costs of diabetes complications were derived from Thai data sources...
July 11, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28635362/costs-and-effectiveness-of-fingolimod-versus-alemtuzumab-in-the-treatment-of-highly-active-relapsing-remitting-multiple-sclerosis-in-the-uk-re-treatment-discount-and-disutility
#8
Stephen M Montgomery, Jeanette Kusel, Richard Nicholas, Nicholas Adlard
OBJECTIVE: Patients with relapsing-remitting multiple sclerosis (RRMS) treated with disease modifying therapies (DMTs) who continue to experience disease activity may be considered for escalation therapies such as fingolimod, or may be considered for alemtuzumab. Previous economic modeling used Markov models; applying one alternative technique, discrete event simulation (DES) modeling, allows re-treatment and long-term adverse events (AEs) to be included in the analysis. METHODS: A DES was adapted to model relapse-triggered re-treatment with alemtuzumab and the effect of including ongoing quality-adjusted life year (QALY) decrements for AEs that extend beyond previous 1-year Markov cycles...
July 11, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28635342/healthcare-costs-in-psoriasis-and-psoriasis-sub-groups-over-time-following-psoriasis-diagnosis
#9
Sarah Al Sawah, Shonda A Foster, Orin M Goldblum, William N Malatestinic, Baojin Zhu, Nianwen Shi, Xue Song, Steven R Feldman
AIMS: To quantify healthcare costs in patients with psoriasis overall and in psoriasis patient sub-groups, by level of disease severity, presence or absence of psoriatic arthritis, or use of biologics. METHODS: Administrative data from Truven Health Analytics MarketScan Research Database were used to select adult patients with psoriasis from January 2009 to January 2014. The first psoriasis diagnosis was set as the index date. Patients were required to have ≥6 months of continuous enrollment with medical and pharmacy benefits pre-index and ≥12 months post-index...
July 11, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28631497/cost-effectiveness-of-blinatumomab-versus-salvage-chemotherapy-in-relapsed-or-refractory-philadelphia-chromosome-negative-b-precursor-acute-lymphoblastic-leukemia-from-a-us-payer-perspective
#10
Thomas E Delea, Jordan Amdahl, Diana Boyko, May Hagiwara, Zachary F Zimmerman, Janet L Franklin, Ze Cong, Guy Hechmati, Anthony Stein
OBJECTIVE: To evaluate the cost-effectiveness of blinatumomab (Blincyto) vs standard of care (SOC) chemotherapy in adults with relapsed or refractory (R/R) Philadelphia-chromosome-negative (Ph-) B-precursor acute lymphoblastic leukemia (ALL) based on the results of the phase 3 TOWER study from a US healthcare payer perspective. METHODS: The Blincyto Global Economic Model (B-GEM), a partitioned survival model, was used to estimate the incremental cost-effectiveness ratio (ICER) of blinatumomab vs SOC...
July 11, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28685629/examining-the-association-of-smoking-with-work-productivity-and-associated-costs-in-japan
#11
Kiyomi Suwa, Natalia M Flores, Reiko Yoshikawa, Rei Goto, Jeffrey Vietri, Ataru Igarashi
AIMS: Smoking is associated with significant health and economic burden globally, including an increased risk of many leading causes of mortality and significant impairments in work productivity. This burden is attenuated by successful tobacco cessation, including reduced risk of disease and improved productivity. The current study aimed to show the benefits of smoking cessation for workplace productivity and decreased costs associated with loss of work impairment. MATERIALS AND METHODS: Data source was the 2011 Japan National Health and Wellness Survey (N = 30,000)...
July 7, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28682153/real-life-cost-of-vitamin-k-antagonist-treatment-in-patients-with-non-valvular-atrial-fibrillation-in-france-in-2013
#12
Jean Dallongeville, Xavier Ansolabehere, Noëlla Karusisi, Maurel Frédérique, Eric Van Ganse, Jean-Yves Le Heuzey
AIMS: Data highlighting the cost drivers for non-valvular atrial fibrillation (NVAF) patients in terms of vitamin K antagonist (VKA) treatment and monitoring are lacking in France. This study aimed to evaluate the real-life daily cost of VKA treatment in 2013, in French patients suffering from NVAF. METHODS: This longitudinal observational study was performed using the EGB (Echantillon Généraliste des Bénéficiaires) database, a random sample of the French national insurance (NHI) database which covers 80% of the population...
July 6, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28681664/evaluation-of-healthcare-resource-utilization-and-incremental-economic-burden-of-patients-with-chronic-myeloid-leukemia-after-disease-progression-to-blast-phase
#13
Elias J Jabbour, Jay Lin, Lisa R Siegartel, Melissa Lingohr-Smith, Brandy Menges, Dinara Makenbaeva
AIMS: To evaluate healthcare resource utilization and economic burden of patients with chronic myeloid leukemia (CML) progression to the blast phase. METHODS: Patients (≥ 18 years) with ≥1 inpatient or ≥2 outpatient CML diagnoses were identified from the MarketScan Commercial and Medicare databases (January 1, 2007-June 30, 2015). CML patients were grouped into two study cohorts, those with evidence of disease progression to the blast phase and those without...
July 6, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28678623/economic-burden-of-sarcoidosis-in-a-commercially-insured-population-in-the-united-states
#14
J Bradford Rice, Alan White, Andrea Lopez, Alexandra Conway, Aneesha Wagh, Winnie W Nelson, Michael Philbin, George J Wan
BACKGROUND: Sarcoidosis is a multisystem inflammatory disorder characterized by the presence of noncaseating granulomas in involved organs. Patients with sarcoidosis have a reduced quality of life and are at an increased risk for several comorbidities. Little is known about the direct and indirect cost of sarcoidosis following the initial diagnosis. AIMS: To provide an estimate of the healthcare resource utilization (HCRU) and costs borne by commercial payers for sarcoidosis patients in the US...
July 5, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28678566/cost-effectiveness-of-3-month-paliperidone-treatment-for-chronic-schizophrenia-in-spain
#15
Thomas R Einarson, Basil G Bereza, Ignacio Garcia Llinares, Beatriz González Martín Moro, Fadi Tedouri, Kristel Van Impe
BACKGROUND: A three-month long treatment of paliperidone palmitate (PP3M) has been introduced as an option for treating schizophrenia. Its cost-effectiveness in Spain has not been established. AIMS: To compare the costs and effects of PP3M compared with once-monthly paliperidone (PP1M) from the payer perspective in Spain. METHODS: We used the recently published trial by Savitz (2016) as a core model over one year. Additional data were derived from the literature...
July 5, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28673116/patterns-of-care-and-burden-of-chronic-idiopathic-thrombocytopenic-purpura-in-brazil
#16
Ana Clara Kneese Virgilio do Nascimento, Joyce Maria Annichino-Bizzacchi, Claudia de Alvarenga Maximo, Eimy Minowa, Guilherme Silva Julian, Rafael Freitas Dos Santos
AIMS: Although several therapeutic options are available for chronic immune thrombocytopenic purpura (cITP), little is known about the treatment of cITP in Brazil. MATERIALS AND METHODS: A multi-center, retrospective chart review, observational study was designed to describe the treatment patterns, clinical burden, resources use, and associated costs for adult patients diagnosed with cITP and treated in public and private institutions in Brazil. Patient charts were screened in reverse chronological order based on their last visit post January 1, 2012...
July 4, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28581874/cost-drivers-for-breast-lung-and-colorectal-cancer-care-in-a-commercially-insured-population-over-a-6-month-episode-an-economic-analysis-from-a-health-plan-perspective
#17
Bhuvana Sagar, Yu Shen Lin, Liana D Castel
AIMS: In the absence of clinical data, accurate identification of cost drivers is needed for economic comparison in an alternate payment model. From a health plan perspective using claims data in a commercial population, the objective was to identify and quantify the effects of cost drivers in economic models of breast, lung, and colorectal cancer costs over a 6-month episode following initial chemotherapy. RESEARCH DESIGN AND METHODS: This study analyzed claims data from 9,748 Cigna beneficiaries with diagnosis of breast, lung, and colorectal cancer following initial chemotherapy from January 1, 2014 to December 31, 2015...
July 3, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28657451/cost-effectiveness-of-dedicated-dietitians-for-hyperphosphatemia-management-among-hemodialysis-patients-in-lebanon-results-from-the-nutrition-education-for-management-of-osteodystrophy-trial
#18
Rana Rizk, Mickaël Hiligsmann, Mirey Karavetian, Silvia M A A Evers
AIM: Assess the cost-effectiveness of nutrition education by dedicated dietitians (DD) for hyperphosphatemia management among hemodialysis patients. MATERIALS AND METHODS: This was a trial-based economic evaluation in 12 Lebanese hospital-based units. 545 prevalent patients were cluster randomized to DD, trained hospital dietitian (THD), and existing practice (EP) groups. During Phase I (6 months), DD (n = 116) received intensive education by DD trained on renal nutrition, THD (n = 299) received care from trained hospital dietitians, and EP (n = 130) received usual care from untrained hospital dietitians...
June 28, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28521540/cost-effectiveness-analysis-of-rivaroxaban-for-treatment-and-secondary-prevention-of-venous-thromboembolism-in-the-netherlands
#19
Marieke Heisen, Maarten J Treur, Harald E Heemstra, Eric B W Giesen, Maarten J Postma
BACKGROUND: Until recently, standard treatment of venous thromboembolism (VTE) concerned a combination of short-term low-molecular-weight heparin (LMWH) and long-term vitamin-K antagonist (VKA). Risk of bleeding and the requirement for regular anticoagulation monitoring are, however, limiting their use. Rivaroxaban is a novel oral anticoagulant associated with a significantly lower risk of major bleeds (hazard ratio = 0.54, 95% confidence interval = 0.37-0.79) compared to LMWH/VKA therapy, and does not require regular anticoagulation monitoring...
June 25, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28604141/cost-effectiveness-of-subdermal-implantable-buprenorphine-versus-sublingual-buprenorphine-to-treat-opioid-use-disorder
#20
John A Carter, Ryan Dammerman, Michael Frost
AIMS: Subdermal implantable buprenorphine (BSI) was recently approved to treat opioid use disorder (OUD) in clinically-stable adults. In the pivotal clinical trial, BSI was associated with a higher proportion of completely-abstinent patients (85.7% vs 71.9%; p = .03) vs sublingual buprenorphine (SL-BPN). Elsewhere, relapse to illicit drug use is associated with diminished treatment outcomes and increased costs. This study evaluated the cost-effectiveness of BSI vs SL-BPN from a US societal perspective...
June 22, 2017: Journal of Medical Economics
journal
journal
34457
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"